NCT01751269View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Healthy VolunteersBacterial Infections
Interventions
DRUG

RPX7009

Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.

DRUG

Placebo

Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.

Trial Locations (1)

5000

CMAX, Adelaide

All Listed Sponsors
lead

Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

INDUSTRY

NCT01751269 - Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter